CARDIO-TTRansform: Eplontersen Fails to Improve Cardiovascular Outcomes When Added to Standard Therapy in ATTR-CM

As reported on Healio, the phase 3 CARDIO-TTRansform study, the largest clinical trial conducted to date in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), found that adding eplontersen to contemporary…

Continue Reading CARDIO-TTRansform: Eplontersen Fails to Improve Cardiovascular Outcomes When Added to Standard Therapy in ATTR-CM

A Breakthrough 50 Years in the Making: FDA Approves First Drug to Directly Target Pancreatic Cancer’s Primary Driver

RASONQUE Represents a Watershed Moment for a Disease That Has Resisted Treatment Since RAS Was Discovered as a Cancer-Causing Gene Pancreatic cancer is among the cruelest malignancies. It develops silently,…

Continue Reading A Breakthrough 50 Years in the Making: FDA Approves First Drug to Directly Target Pancreatic Cancer’s Primary Driver